Hepato Care Products

Derma Care

Viral hepatitis, caused by hepatitis viruses A through E, is a significant public health problem in India. An estimated 40 million people in India have chronic hepatitis B infection, constituting approximately 11% of the estimated global burden. Hepatitis C affects about 12 million patients in India (WHO Data). Both of these blood-borne infections have high risk of chronicity with progression to advanced liver disease and are associated with development of hepatocellular carcinoma, a type of liver cancer, underscoring the need for increased access to high quality, affordable and effective therapy in India.

Mylan India launched its Hepato Care division in January 2015 to respond to this public health concern and help meet the unmet medical needs of the patients in India who do not currently have access to critical medicines. 

  • MyDekla60TM

    Daclatasvir Dihydrochloride tablets 
    Strength: 60mg
    Primary Pack : HDPE Bottle Containing 28 tablets

  • MyHepTM

    Sofosbuvir Tablets
    Strength: 400mg 
    Primary Pack : HDPE Bottle Containing 28 tablets

  • MyHep AllTM

    Fixed-dose combination tablet containing Sofosbuvir/ Velpatasvir 
    Strength: Sofosbuvir 400 mg + Velpatasvir 100 mg
    Primary Pack : Bottle contains 28 tablets

  • MyHep LVIRTM

    Ledipasvir & Sofosbuvir Tablets
    Strength: 90mg Ledipasvir & 400mg Sofosbuvir
    Primary Pack : HDPE Bottle Containing 28 tablets

  • RicovirTM

    Tenofovir Disoproxil Fumarate Tablets IP
    Strength: 300mg 
    Primary Pack : HDPE bottle containing 30 film coated tablets

  • SovaldiĀ®

    Sofosbuvir Tablets
    Strength: 400 mg
    Primary Pack: HDPE bottle containing 28 film coated tablets

The product database is intended as a general reference source only and is not a substitute for qualified medical care from a licensed physician.

Sovaldi and the Sovaldi logo are registered trademarks of Gilead Sciences Inc

Expanding Access
to Hepatitis Treatments

Mylan is working with partners like Gilead Sciences to help expand access to innovative hepatitis medicines in India.

  • Questions?

    Get more information on our products, services and Mylan Global Center locations.

    Contact Us

  • Business Opportunities

    Do you have an opportunity or a collaboration idea?

    Partner with us